Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

2022 High Conviction: Tail Winds for Jinxin Fertility

Jinxin Fertility: Shenzhen and Yunnan Acquisitions

Jinxin Fertility 1H2021: A Clear Picture of the Long Term Potential

Jinxin Fertility: Signs of Policy Tailwind and Valuation Dislocation

Jinxin Fertility: Takeaways from Wuhan NDR and Yunnan Acquisition

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

Jinxin Fertility Group  / Equity Bottom-Up

<p>Jinxin Fertility announced that it is acquiring the Jinxin Woman and Children Hospital from its main shareholder with a mix of cash and convertible bond. We attended the call which provided more details of the transaction and the rationale behind. While the transaction is EPS accretive to the listed company and the explanation makes sense as to capture more value over the O&amp;B value chain, we do think the acquisition could be viewed as controversial. Though we continue to like the company, we think there could be de-rating of the PER multiple due to increasing contribution from traditional O&amp;B business.  </p>

Jinxin Fertility announced that it is acquiring the Jinxin Woman and Children Hospital from its main shareholder with a mix of cash and convertible bond. We attended the call which provided more details of the transaction and the rationale behind. While the transaction is EPS accretive to the listed company and the explanation makes sense as to capture more value over the O&amp;B value chain, we do think the acquisition could be viewed as controversial. Though we continue to like the company, we think there could be de-rating of the PER multiple due to increasing contribution from traditional O&amp;B business.  

Jinxin Fertility: Accretive but Slightly Controversial Acquisition of Jinxin WCH